Checkmate Pharmaceuticals, Inc.
CMPIInactive ticker- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
No open-market purchases or sales by Checkmate Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
13F holders, Q2 2022
Institutional positions in Checkmate Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 0
- −26 vs. Q1 2022
- Shares held
- 0
- −17.2M (−100.0%) vs. Q1 2022
- Total value
- $0
- −$54.8M (−100.0%) vs. Q1 2022
- New holders
- 0
- 0 more added
- Sold out
- 26
- 0 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 26 | $54.8M |
| Q4 2021 | 25 | $46.3M |
| Q3 2021 | 31 | $64.6M |
| Q2 2021 | 34 | $97.3M |
| Q1 2021 | 37 | $202.5M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Checkmate Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 0 | $0 | 0.00% | −1,501,716−100.0% | Sold out |
| venBio Partners LLC | 0 | $0 | 0.00% | −3,673,374−100.0% | Sold out |
| Sofinnova Investments, Inc. | 0 | $0 | 0.00% | −3,606,707−100.0% | Sold out |
| Novo Holdings A/S | 0 | $0 | 0.00% | −2,161,990−100.0% | Sold out |
| Omega Fund Management, LLC | 0 | $0 | 0.00% | −1,335,050−100.0% | Sold out |
| Decheng Capital Management III (Cayman), LLC | 0 | $0 | 0.00% | −1,333,254−100.0% | Sold out |
| Clough Capital Partners L P | 0 | $0 | 0.00% | −1,137,764−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −966,226−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −556,423−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −541,765−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −106,500−100.0% | Sold out |
| RBF Capital, LLC | 0 | $0 | 0.00% | −68,034−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −51,334−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −41,466−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −30,636−100.0% | Sold out |
| Cambridge Trust Co | 0 | $0 | 0.00% | −24,609−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −14,553−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −11,424−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −3,005−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,940−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −183−100.0% | Sold out |
| Johnson Midwest Financial, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −49−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −33−100.0% | Sold out |